2011年度

廣田豪、高根浩、鰤岡直人、清水英治、中村廣繁、大坪健司、家入一郎. microRNAによるdihydropyrimidine dehydrogenase遺伝子発現抑制機構の解明. 臨床薬理の進歩 32:115-126(2011)

2010年度

Sasaki T, Takane H, Ogawa K, Isagawa S, Hirota T, Higuchi S, Horii T, Otsubo K, Ieiri I (2011) Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob Agents Chemother.55(5):1867-73.

森田俊博、高根　浩、大坪健司、家入一郎: 食品用粘度調整剤と嚥下補助剤の体内動態への影響. 医療薬学37:13-19, 2011

金田達也、大谷誠司、高根 浩、椎木芳和、林原正和、大坪健司：一包化調剤における配合変化情報の認識度と情報提供に伴う認識度および調剤方法の変化. 医療薬学 37: 187-193 (2011).

2009年度

Takane H, Kawamoto K, Sasaki T, Moriki K, Moriki K, Kitano H, Higuchi S, Otsubo K, Ieiri I (2009) Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy. Cancer Chemother Pharmacol. 63(6):1165-9

高根 浩、島田耕太郎、小川勝弘、大坪健司：ボリコナゾールによる肝障害に関するレトロスペクティブ調査. 医療薬学 35: 579-584 (2009).

金田達也、大谷誠司、林原正和、涌嶋伴之助、秦英司、椎木芳和、大坪健司：一包化調剤の現状と安定性情報の適正利用に関する評価. 日本病院薬剤師会雑誌 45: 1599-1604（2009）．

2008年度

Takaki Y, Kaminou T, Shabana M, Ihara T, Otsubo K, Ogawa T (2008) Suitable Bleeding Method of Lipiodol-cisplatin in Transcatheter Arterial Embolization for Hepatocellula Carcinoma : Evaluation of Sustained Release and Accumulation Nature. Hepato-Gastroenterilogy 55:202-6.

金田達也，林原正和，松田吉弘，涌嶋伴之助，秦英司，椎木芳和，大坪健司：「後発医薬品への変更可」処方せんにおける後発医薬品の継続性に関する実態調査，日本病院薬剤師会雑誌，44，913-916（2008）．

2007年度

Shikata E, Yamamoto R, Takane H, Shigemasa C, Ikeda T, Otsubo K, Ieiri I (2007)Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet 52: 117-22.

Takane H, Miyata M, Burioka N, Kurai K, Fukuoka Y, Suyama H, Shigeoka Y, Otsubo K, Ieiri I, Shimizu E(2007)Severe toxicities following irinotecan-based chemotherapy in a lung cancer patient, a homozygote for SLCO1B1*15 allele. Ther Drug Monit 29: 666-8.

金田達也、田邊靖子、椎木芳和、林原正和、大坪健司　処方せん様式変更に伴う後発医薬品への変更に関する実態調査.　日本病院薬剤師会雑誌43: 823-826 .

金田達也、田邊靖子、細川和代、涌嶋伴之助、秦　英司、椎木芳和、寺本圭、林原正和、大坪健司　鳥取大学医学部附属病院における持参薬の実態と調査業務量の分析.　医療薬学 33: 719-724 .

小川 勝弘、高根 浩、阪本 絵理子、長谷川 賢作、北野 博也、大坪 健司 MRSA中耳炎患者で塩酸バンコマシン投与後に多発したレッドマン症候群の要因解析と対応. 日本病院薬剤師会雑誌 43: - .

2006年度

Miyata M, Yasuda K, Burioka N, Takane H, Suyama H, Shigeoka Y, Endo M, Kurai J, Morita M, Igishi T, Shimizu E (2006) The influence of granisetron on the pharmacokinetics and pharmacodynamics of docetaxel in asian lung cancer patients. Cancer J 12:69-72.

Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, Hirano M, Watanabe T, Kitamura Y, Kusuhara H, Sugiyama Y (2006) Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 79:427-39.

Shikata E, Ieiri I, Ishiguro S, Takane H, Ohgi S and Otsubo K (2006) Multiple gene polymorphisms and warfarin sensitivity. Eur J Clin Pharmacol 62:881-3

Koyanagi S, Suyama H, Kuramoto Y, Matsunaga N, Takane H, Soeda S, Shimeno H, Higuchi S and Ohdo S (2006) Glucocorticoid regulation of 24-hour oscillation in interferon receptor gene expression in mouse liver. Endocrinology 147:5034-5040.

Takane H, Miyata M, Burioka N, Shigemasa C, Shimizu E, Otsubo K and Ieiri I (2006) Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. J Hum Genet 18:822-6.

2005年度

Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, Kigawa J, Suzuki H, Nanbe E, Oshimura M, Terakawa N, Otsubo K, Mine K and Sugiyama Y (2005) Functional assessment of abcg2 (bcrp) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 33: 94-101

Burioka N, Takata M, Okano Y, Ohdo S, Fukuoka Y, Miyata M, Takane H, Endo M, Suyama H, Shimizu E (2005) Dexamethasone influences human clock gene expression in bronchial epithelium and peripheral blood mononuclear cells in vitro. Chronobiol Int 22:585-90.

Takane H, Nosaka A, Wakushima H, Hosokawa K, Ieiri I (2005) Rifampicin reduces the analgesic effect of transdermal fentanyl. Ann Pharmacother 39: 2139-40.

Ieiri I, Kimura M, Irie S, Urae A, Otsubo K, Ishizaki T (2005) Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status. Pharmacogenet Genomics 15: 851-859.

2004年度

Shikata E, Ieiri I, Ishiguro S, Aono H, Inoue K, Koide T, Ohgi S and Otsubo K (2004) Association of pharmacokinetic (CYP2C9) and pharmacodynamic (vitamin K-dependent protein-factors II, VII, IX, and X, proteins S and C, and [gamma]-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 103: 2630-2635

Takahashi H, Ieiri I, Wilkinson GR, Mayo G, Kashima T, Kimura S, Otsubo K and Echizen H (2004) 5'-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. Blood 103: 3055-3057

Hirouchi M, Suzuki H, Itodo M, Ozawa S, Sawada J, Ieiri I, Otsubo K and Sugiyama Y (2004) Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2. Pharm Res 21: 742-748

Takane H, Kobayashi D, Hirota T, Kigawa J, Terakawa N, Otsubo K and Ieiri I (2004) Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene. J Pharmacol Exp Ther 311: 1179-1187

Hirota T, Ieiri I, Takane H, Maegawa S, Hosokawa M, Kobayashi K, Chiba K, Nanba E, Oshimura M, Sato T, Higuchi S and Otsubo K (2004) Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status. Hum Mol Genet 13: 2959-2969

Ieiri I, Suzuki H, Kimura M, Takane H, Nishizato Y, Irie S, Urae A, Kawabata K, Higuchi S, Otsubo K and Sugiyama Y (2004) Influence of common variants in the pharmacokinetic genes (OATP-C, UGT1A1, and MRP2) on serum bilirubin levels in healthy subjects.Hepatol Res 30: 91-95

Kondo C, Suzuki H, Itoida M, Ozawa S, Sawada J, Kobayashi D, Ieiri I, Mine K, Otsubo K and Sugiyama Y (2004) Functional analysis of SNPs variants of BCRP/ABCG2 Pharm Res 21: 1895-1903

Iwai M, Suzuki H, Ieiri I, Otsubo K and Sugiyama Y (2004) Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 14: 749-757

Saito M, Watanabe T, Tabuchi F, Otsubo K, Satoh K, Miyagawa I (2004) Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience. Int J Urol 11: 592-596

Teshima D, Otsubo K, Makino K, Itoh Y and Oishi R (2004) Simultaneous
determination for sulfamethoxazole and torimetoprime in human plasma with
capillary zone electrophoresis. Biomed. Chromatogr. Biomed Chromatogr 18: 51-54.

2003年度

Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, Urae A, Higuchi S, Otsubo K and Sugiyama Y (2003) Polymorphisms of OATP-C(SLC21A6) and OAT3(SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73: 554-565

Hirota T, Ieiri I, Takane H, Sano H, Kawamoto K, Aono H, Yamasaki A, Takeuchi H, Masada M, Shimizu E, Higuchi S and Otsubo K (2003) Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab Dispos 31: 677-680

Ieiri I, Yamada S, Seto K, Morita T, Kaneda T, Mamiya K, Tashiro N, Higuchi S and Otsubo K (2003) A CYP2D6 phenotype-genotype mismatch in Japanese psychiatric patients. Pharmacopsychiatry 36: 1-5

Yoshida M, Ohdo S, Takane H, Tomiyoshi Y, Matsuo A, Yukawa E and Higuchi S (2003) Chronopharmacology of analgesic effect and its tolerance induced by morphine in mice. J Pharmacol Exp Ther 305: 1200-1205

Nakayasu H, Maeda M, Soda T, Iijima K, Ishimoto M, Ieiri I, Tabuchi F, Otsubo K and Nakashima K (2003) The antiplatelet anggregation effects of aspirin suppositories. Cerebrovasc Dis 16: 31-35

Teshima D, Otsubo K, Yoshida T, Itoh Y and Oishi R (2003) A simple and simultaneous determination of acyclovir and ganciclovir in human plasma by high-performance liquid chromatography. Biomed Chromatogr 17: 500-503.

2002年度

Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, Ohdo S, Ohtani H, Sawada Y, Higuchi S and Otsubo K (2002) Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 72

Yamauchi A, Ieiri I, Kataoka Y, Tanabe M, Nishizaki T, Oishi R, Higuchi S, Otsubo K and Sugimachi K (2002) Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 74

Urae A, Okada M, Ieiri I, Higuchi S, Hisaoka M, Tajima M, Ogihara T and Nakano S (2002) Contribution of angiotensin converting enzyme gene polymorphism to the action of angiotensin II receptor antagonist (CS-866). Jpn J Clin Pharmacol Ther 33: 37-46.

Takane H, Ohdo S, Baba R, Koyanagi S, Yukawa E and Higuchi S (2002)Relationship between 24-hour rhythm in antiviral effect of interferon-β and interferon-α/β receptor expression in mice. Jpn J Pharmacol 90: 304-312

Takata M, Burioka Ohdo S, Takane H, Terazono H, Miyata M, Sako T, Suyama H, Fukuoka Y, Tomita K and Shimizu E (2002) Daily expression of mRNAs for the mammalian clock genes Per2 and Clock in mouse suprachiasmatic nuclei and liver and human peripheral blood mononuclear cells. Jpn J Pharmacol 90: 263-269

Honda T, Dan Y, Koyabu N, Ieiri I, Otsubo K, Higuchi S, Ohtani H and Sawada Y (2002) Polymorphism of MDR1 gene in healthy Japanese subjects: a novel SNP with an amino acid substitution (Glu108Lys). Drug Metab Pharmacokin 17: 479-481.

2001年度

Mamiya K, Kojima K, Yukawa E, Higuchi S, Ieiri I, Ninomiya H and Tashiro N (2001) Phenytoin intoxication induced by fluvoxamine. Ther Drug Monit 23: 75-77.

Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S and Otsubo K (2001) Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 11: 175-184.

Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N and Otsubo K (2001) Expression of P-glycoprotein in human Placenta: Relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297: 1137-1143.

Ieiri I, Kishimoto Y, Okochi H, Momiyama K, Morita T, Kitano M, Morisawa T, Fukushima Y, Nakagawa K, Hasegawa J, Otsubo K and Ishizaki T (2001) Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism. Eur J Pharmacol 57: 485-492.

Shintani M, Ieiri I, Inoue K, Mamiya K, Ninomiya H, Tashiro N, Higuchi S and Otsubo K (2001) Genetic polymorphism and functional characterization of the 5’-flanking region of the human CYP2C9 gene: In vitro and in vivo studies. Clin Pharmacol Ther 70: 175-182.

2000年度

Mamiya K, Hadama A, Yukawa E, Ieiri I, Otsubo K, Ninomiya H, Tashiro N and Higuchi S (2000) CYP2C19 polymorphism effect on phenobarbitone. Pharmacokineties in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur J Clin Pharmacol 55:821-825.

Shimamoto J, Ieiri I, Urae A, Kimura M, Irie S, Kubota T, Chiba K, Ishizaki T, Otsubo K and Higuchi S (2000) Lack of differences in diclofenac (a substrate for CYP2C9) pharmacikinetics in healthy volunteers with respect to the single CYP2C9*3 allele. Eur J Clin Pharmacol 56: 65-68.

Ninomiya H, Mamiya K, Matsuo S, Ieiri I, Higuchi S and Tashiro N (2000) Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin cencentration with central nervous system intoxication. Ther Drug Monit 22: 230-232.

Ieiri I, Taninaka H, Morita T, Hadama A, Mamiya K, Hayashibara M, Ninomiya H, Ohmori S, Kitada M, Tashiro N, Higuchi S and Otsubo K (2000) Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. Ther Drug Monit 22: 237-244.

Imai J, Ieiri I, Mamiya K, Miyahara S, Furuumi H, Nanba E, Yamane M, Fukumaki Y, Ninomiya H, Tashiro N, Otsubo K and Higuchi S (2000) Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics 10: 85-89.

1998-1999年度

Mamiya K, Ieiri I, Shimamoto J, Yukawa E, Imai J, Ninomiya H, Yamada H, Otsubo K, HiguchiS and Tashiro N (1998) The effects of genetic polymorphisms of CYP2C9 and CYPC19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 39: 1317-1323.

Kimura M, Ieiri I, Wada Y, Mamiya K, Urae A, Iimori E, Sakai T, Otsubo K and Higuchi S (1999) Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy. Br J Clin Pharmacol 47: 115-119.